Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-2304 in Healthy Participants and Participants with SLE or CLE
NCT06625671Phase 2Recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Oct 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of DB-2304 in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (8 arms), sponsored by Duality Biotherapeutics. Primary endpoints: Treatment-Emergent Adverse Events, Serious Adverse Events and 6 more. Started Oct 2024; status: recruiting.
02
Drugs
DB-2304
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT06625671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625671.